WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies


WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost for manufacturing cell and gene therapies, enabling global customers to deliver more accessible ground-breaking therapeutics to patients as quickly as possible.

Read More

Next Post

Rakuten Medical Announces New Name "Alluminox™" for its Proprietary Technology Platform

Rakuten Medical, Inc. (Rakuten Medical) has elected to discontinue use of  the name “Illuminox,” and to start using a new, evolved name “Alluminox™” for our proprietary, anti-cancer, photoimmunotherapy technology platform, which is comprised of drug, medical device, and other related technologies. This name change will take effect globally from April […]